119981-84-9

Upstream product

• 867-13-0 diethoxyphosphoryl-acetic acid ethyl ester 
• 59591-01-4 2,2-diphenylcyclopropanecarbaldehyde 
• 1099-45-2 ethyl (triphenylphosphoranylidene)acetate 
• 908093-98-1 diazodiphenylmethane 
• 67428-04-0 ethyl 2,2-diphenylcyclopropane-1-carboxylate 
• 37555-48-9 2,2-diphenylcyclopropylmethanol 
• 5350-57-2 benzophenone hydrazone 
• 119-61-9 benzophenone 
• 530-48-3 1,1-Diphenylethylene 

Downstream Products

• 936140-32-8 methyl 3-(tert-butyl((E)-3-(2,2-diphenylcyclopropyl)-2-propenyl)amino)-3-oxopropanoate 
• 936140-31-7 (E)-N-tert-butyl-3-(2,2-diphenylcyclopropyl)prop-2-en-1-amine 
• 936140-30-6 (E)-3-(2,2-diphenylcyclopropyl)prop-2-en-1-ol 

Relevant academic research and scientific papers

Facile and efficient way to synthesize the radical cyclization precursor methyl 3-(tert-butyl((E)-3-(2,2-diphenylcyclopropyl)-2-propenyl)amino)-3-oxo-2- (phenylseleno)propanoate for kinetic research

Methyl 3-(tert-butyl((E)-3-(2,2-diphenylcyclopropyl)-2-propenyl)amino)-3- oxo-2-(phenylseleno)propanoate was prepared in 10 steps in good to excellent yield using benzophenone and hydrazine hydrate as the starting materials. Copyright Taylor & Francis Group, LLC.

Cyclopropylpropenamides

The invention relates to compounds of the formula STR1 Y is O or S, *A is paraphenylene or *--(CH2)n --(X)m --(CH2)r --, X is O, S or --CH=CH--, n or r, independently, are integers from 0 to 3, s is an integer from 0 to 1, m is an integer from 0 to 1, provided that when m is 1, n+s must be at least 2, R1 and R2, independently, are hydrogen, lower alkyl, cycloalkyl, lower alkenyl, Het or aryl, *E is STR2 or --(CH2)k -- wherein k is an integer from 0 to 4, R3, R4 and R8 are independently hydrogen or lower alkyl, R5 and R6, independently are hydrogen or lower alkyl, R7 is hydrogen, lower alkyl, cycloalkyl, Het-lower alkyl or aryl, Het is a monocyclic 5- or 6-membered hetero aromatic or a bicyclic heteroaromatic radical containing one or two hetero atoms selected from nitrogen, oxygen and sulfur, which radical may be substituted by lower alkyl, halogen or aryl, and the asterisk denotes the point of attachment, and their enantiomers, diastereomers and racemic mixtures thereof, as well as when *E is STR3 their geometric isomers, and pharmaceutically acceptable acid addition salts thereof. The compounds of formula I exhibit activity as platelet activating factor (PAF) antagonists and are, therefore, useful in disease states characterized by excess platelet activating factor or for the prevention and treatment of cardiovascular diseases, pulmonary diseases, immunological disorders, inflammatory diseases, dermatological disorders, shock or transplant rejection.